title: Synthesis and characterization of lipid immuno-nanocapsules for directed drug delivery: selective antitumor activity against HER2 positive breast-cancer cells.
abstract: Lipid nanocapsules (LNC) are usually developed as nanocarriers for lipophilic drug delivery. The surface characteristics of these colloidal particles are determinant for a controlled and directed delivery to target tissues with specific markers. We report the development of immuno-nanocapsules, in which some antibody molecules with different immuno-specificity are conjugated to the nanocapsule surface, offering the standardization of a simple method to obtain vectorized nanosystems with specific recognition properties. Nanocapsules were prepared by a solvent-displacement technique, producing an oily core coated by a functional shell of different biocompatible molecules and surface carboxylic groups. Three different antibodies (one a specific HER2 oncoprotein antibody) were conjugated with these nanoparticles by the carbodiimide method, which allows the covalent immobilization of protein molecules through carboxylic surface groups. The immuno-nanocapsules were completely characterized physico-chemically via electrokinetic and colloidal stability experiments, confirming the correct immobilization of these antibody molecules on the colloidal nanoparticles. Also, additional immunological analyses verified that these IgG-LNC complexes showed the expected specific immuno-response. Finally, different healthy and tumoral breast-cell lines were cultured in vitro with Nile-Red-loaded and docetaxel-loaded HER2 immuno-nanocapsules. The results indicate that our immuno-nanocapsules can increase their uptake in HER2 overexpressing tumoral cell lines.
authors.affiliation: Biocolloid and Fluid Physics Group, Department of Applied Physics, University of Granada , 18071 Granada, Spain.
authors.forename: Paola
authors.initials: P
authors.lastname: Sánchez-Moreno
authors.forename: Juan Luis
authors.initials: JL
authors.lastname: Ortega-Vinuesa
authors.forename: Houría
authors.initials: H
authors.lastname: Boulaiz
authors.forename: Juan Antonio
authors.initials: JA
authors.lastname: Marchal
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Peula-García
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D001943:Breast Neoplasms; D003102:Colloids; D003840:Deoxycholic Acid / Q000737:chemistry; D000077143:Docetaxel; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D020128:Inhibitory Concentration 50; D061986:MCF-7 Cells; D053769:Nanocapsules / Q000737:chemistry*; D000069463:Olive Oil; D010316:Particle Size; D010938:Plant Oils / Q000737:chemistry*; D020442:Poloxamer / Q000737:chemistry; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D043823:Taxoids / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003102:Colloids; D003840:Deoxycholic Acid; D000077143:Docetaxel; D053769:Nanocapsules; D000069463:Olive Oil; D010938:Plant Oils; D020442:Poloxamer; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab; C508053:ERBB2 protein, human